This study is looking at how reducing high insulin levels in people with type 1 diabetes might improve heart and blood sugar health. Researchers will use a medication called empagliflozin (an SGLT2 inhibitor) to help the body get rid of sugar and potentially lower insulin needs. They will compare this to a placebo. The study will also include people with a specific type of diabetes called GCK-MODY and healthy volunteers to help understand the results. The goal is to see if this approach can lead to better insulin response and improved blood vessel function. You might be able to join if you are 18-60 years old with type 1 diabetes, GCK-MODY, or are a healthy volunteer. The study is currently unclear on its recruitment status and plans to enroll 27 participants.

Study design

This is an interventional study, meaning participants will receive specific treatments. It involves randomizing participants to different treatment sequences during two study visits.

What's involved

You would participate in two study visits, each involving a hyperinsulinemic, euglycemic clamp (a procedure to control blood sugar and insulin) and a flow-mediated dilation (FMD) study (to check blood vessel function).

Compensation

Not stated in the trial record.

Follow-up

The primary outcomes, tissue glucose disposal and nitric oxide bioavailability, are measured at 8 hours after the start of the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.